| Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs E Degagné, A Pandurangan, P Bandhuvula, A Kumar, A Eltanawy, ... The Journal of clinical investigation 124 (12), 5368-5384, 2014 | 149 | 2014 |
| Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP DM Grbic, E Degagné, C Langlois, AA Dupuis, FP Gendron The Journal of Immunology 180 (4), 2659-2668, 2008 | 147 | 2008 |
| P2Y2 receptor transcription is increased by NF-κB and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells E Degagné, DM Grbic, AA Dupuis, EG Lavoie, C Langlois, N Jain, ... The Journal of Immunology 183 (7), 4521-4529, 2009 | 81 | 2009 |
| Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay M Gallotta, H Assi, É Degagné, SK Kannan, RL Coffman, C Guiducci Cancer research 78 (17), 4943-4956, 2018 | 63 | 2018 |
| P2Y6 Receptor Contributes to Neutrophil Recruitment to Inflamed Intestinal Mucosa by Increasing Cxc Chemokine Ligand 8 Expression in an AP-1-dependent … DM Grbic, E Degagne, JF Larrivée, MS Bilodeau, V Vinette, G Arguin, ... Inflammatory bowel diseases 18 (8), 1456-1469, 2012 | 62 | 2012 |
| S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer E Degagné, JD Saba Clinical and experimental gastroenterology, 205-214, 2014 | 59 | 2014 |
| Sphingosine-1-phosphate signaling and metabolism gene signature in pediatric inflammatory bowel disease: a matched-case control pilot study JH Suh, É Degagné, EE Gleghorn, M Setty, A Rodriguez, KT Park, ... Inflammatory bowel diseases 24 (6), 1321-1334, 2018 | 35 | 2018 |
| S1P lyase regulation of thymic egress and oncogenic inflammatory signaling A Kumar, J Zamora-Pineda, E Degagné, JD Saba Mediators of Inflammation 2017, 2017 | 27 | 2017 |
| P2Y2 receptor promotes intestinal microtubule stabilization and mucosal re‐epithelization in experimental colitis É Degagné, J Degrandmaison, DM Grbic, V Vinette, G Arguin, ... Journal of cellular physiology 228 (1), 99-109, 2013 | 24 | 2013 |
| P2Y2 receptor expression is regulated by C/EBPβ during inflammation in intestinal epithelial cells E Degagne, N Turgeon, J Moore‐Gagné, C Asselin, FP Gendron The FEBS Journal 279 (16), 2957-2965, 2012 | 16 | 2012 |
| P2y (2) receptor promotes intestinal epithelial cell migration through a go protein and integrin alpha (v) pathway allowing microtubule stabilization and mucosal re … E Degagne, J Degrandmaison, DM Grbic, V Vinette, G Arguin, ... J Cell Physiol 228, 99-109, 2012 | 7 | 2012 |
| Tumor abscopal responses induced by the TLR9 agonist, SD-101, are strongly potentiated by a HDAC class I inhibitor, domatinostat É Degagné, J Romo, M Gallotta, S Kannan, RL Coffman, C Guiducci Cancer Research 79 (13_Supplement), 2259-2259, 2019 | 3 | 2019 |
| High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models É Degagné, PD Donohoue, S Roy, J Scherer, TW Fowler, RT Davis, ... Cancer Immunology Research, 2024 | 2 | 2024 |
| Intestinal inflammation increases P2Y6 receptor expression on epithelial cells and the release of CXCL8 by UDP D Grbic, E Degagne, C Langlois, AA Dupuis, FP Gendron Purinergic Signalling 4, S184-S184, 2008 | 2 | 2008 |
| Abstract LB009: a BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection E Garner, E Degagne, S Roy, P Donohoue, T Fowler, M Stanaway, ... Cancer Research 82 (12_Supplement), LB009-LB009, 2022 | 1 | 2022 |
| Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models B Francica, E Garner, S Namburi, C Colgan, T Fowler, D Mutha, A Aviles, ... Cancer Research 84 (6_Supplement), 6323-6323, 2024 | | 2024 |
| CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia B Francica, E Garner, S Namburi, C Colgan, T Fowler, D Mutha, A Aviles, ... Blood 142, 6838, 2023 | | 2023 |
| CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune … E Garner, E Kelly, S Namburi, C Colgan, T Fowler, D Mutha, A Aviles, ... Cancer Research 83 (7_Supplement), 3201-3201, 2023 | | 2023 |
| CB-011, a BCMA-Specific Allogeneic CAR-T Cell Therapy, Engineered with Next-Generation CRISPR Technology to Express an HLA-E Fusion Transgene to Prevent Immune Cell-Mediated … E Garner, E Degagne, S Roy, P Donohoue, T Fowler, M Stanaway, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | | 2023 |
| A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection E Garner, E Degagne, S Roy, P Donohoue, T Fowler, M Stanaway, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
